Limits...
Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus

A pathway of “regulation of smooth muscle cell proliferation” was generated by the GePS program from Genomatix that connects the DEGs found after DG treatment for 12 months.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3794622&req=5

fig7: A pathway of “regulation of smooth muscle cell proliferation” was generated by the GePS program from Genomatix that connects the DEGs found after DG treatment for 12 months.

Mentions: The biological processes were presented by an AmiGo gene ontology (GO) database via the Genomatix Pathway System (GePS) for extracting DEGs relationships based on information extracted from public proprietary databases. The two most important biological processes of “regulation of systemic arterial blood pressure by hormone” and “regulation of smooth muscle proliferation” were identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. For the biological process of “regulation of systemic arterial blood pressure by hormone,” six genes were identified with a P value of 5.98 × 10−5. For the biological process of “regulation of smooth muscle proliferation,” seven genes were identified with a P-value of 1.79 × 10−3. These identified genes are shown in orange color while the co-citation genes are shown in grey color in Figures 6 and 7.


Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.

Koon CM, Ko CH, Sun XX, Hoi SW, Tam JC, Cheung DW, Cheng KF, Pang SY, Lo WM, Chook P, Lau CB, Chan WY, Leung PC, Kwok TC, Fung KP - Evid Based Complement Alternat Med (2013)

A pathway of “regulation of smooth muscle cell proliferation” was generated by the GePS program from Genomatix that connects the DEGs found after DG treatment for 12 months.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3794622&req=5

fig7: A pathway of “regulation of smooth muscle cell proliferation” was generated by the GePS program from Genomatix that connects the DEGs found after DG treatment for 12 months.
Mentions: The biological processes were presented by an AmiGo gene ontology (GO) database via the Genomatix Pathway System (GePS) for extracting DEGs relationships based on information extracted from public proprietary databases. The two most important biological processes of “regulation of systemic arterial blood pressure by hormone” and “regulation of smooth muscle proliferation” were identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. For the biological process of “regulation of systemic arterial blood pressure by hormone,” six genes were identified with a P value of 5.98 × 10−5. For the biological process of “regulation of smooth muscle proliferation,” seven genes were identified with a P-value of 1.79 × 10−3. These identified genes are shown in orange color while the co-citation genes are shown in grey color in Figures 6 and 7.

Bottom Line: For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group.No significant biological process and cellular components were identified in the placebo-treated group.This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

View Article: PubMed Central - PubMed

Affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong ; State Key Laboratory of Phytochemistry & Plant Resources in West China, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.

ABSTRACT
The Danshen-Gegen formula (DG) is a traditional Chinese herbal formula which has long been used to treat cardiovascular disease. DG was found to be a cardiovascular tonic in our recent research. However, a comprehensive investigation of the molecular mechanism of DG in cardiovascular disease has not been performed. The aim of this study was to clarify the transcriptional profiling of genes modulated by DG on postmenopausal women by using DNAmicroarray technology. We obtained 29 whole blood samples both from DG-treated and placebo-treated subjects. Blood lipid profile and intima-media thickness (IMT) were measured. Affymetrix GeneChip was used to identify differentially expressed genes (DEGs), followed by validation by the real-time PCR method. The results showed that DG-treated group has a significant improvement in IMT and lipid profile as compared to placebo-treated group. For the genomic study, the DG-treated group has a higher number of DEGs identified as compared to the placebo-treated group. Two important biological processes of "regulation of systemic arterial blood pressure by hormone" and "regulation of smooth muscle proliferation" have been identified by GePS in the DG-treated group. No significant biological process and cellular components were identified in the placebo-treated group. This genomic study on the molecular action of DG in postmenopausal women gathered sufficient molecular targets and pathways to reveal that DG could improve neointima thickening and hypertension.

No MeSH data available.


Related in: MedlinePlus